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Disparities in the surgical staging of
high-grade endometrial cancer in the
United States
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Mohamed A. Adam3, Angeles Alvarez Secord1, Monica B. Jones1, Junzo Chino5 and Laura J. Havrilesky1
Abstract
Background: The National Comprehensive Cancer Network (NCCN) and the Society of Gynecologic Oncology (SGO)
recommend lymph node sampling (LNS) as a key component in the surgical staging of high-grade endometrial cancer.
Our goal was to examine surgical staging patterns for high-grade endometrial cancer in the United States.
Methods: The National Cancer Data Base (NCDB) was searched for patients who underwent surgery for serous, clear
cell, or grade 3 endometrioid endometrial cancer. Outcomes were receipt of LNS and overall survival (OS). Multivariate
logistic regression was used to examine receipt of LNS in Stage I–III disease based on race (White vs. Black), income,
surgical volume, and distance traveled to care. Multivariate Cox proportional hazards regression modeling was used to
assess OS based on stage, race, income, LNS, surgical volume, and distance traveled.
Results: Forty-two thousand nine hundred seventy-three patients were identified: 76% White, 53% insured by
Medicare/Medicaid, 24% traveled >30 miles, and 33% stage III disease. LNS was similar among White and Black women
(81% vs 82%). LNS was more common among >30 miles traveled (84% vs 81%, p < 0.001), higher surgical volume (83%
vs 80%, p < 0.001), and academic centers (84% vs 80%, p < 0.001). In multivariate analysis, higher income, higher
surgical volume, Charlson-Deyo score, and distance traveled were predictors of LNS. Stage III
disease (HR 3.39, 95% CI 3.28–3.50), age (10-year increase; HR 1.63, 95% CI 1.61–1.66), lack of LNS (HR 1.64,
95% CI 1.56–1.69), and low income (HR 1.20, 95% CI 1.14–1.27) were predictors of lower survival.
Conclusions: Surgical care for high-grade endometrial cancer in the United States is not uniform. Improved access to
high quality care at high volume centers is needed to improve rates of recommended LNS.
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Background
Endometrial cancer is the most common form of gyneco-
logic cancer in the United States, with more than 60,000
new cases and 10,470 deaths estimated to occur in 2016
[1]. The majority of endometrial cancers are Type I, grade
1–2 endometrioid adenocarcinoma and have an excellent
prognosis, most often presenting as low-grade and at an
early stage. Conversely, Type II cancers, including uterine
papillary serous carcinoma (UPSC), clear cell carcinoma
(CC), and grade 3 endometrioid adenocarcinoma, often
have a much worse prognosis, presenting with extra-
uterine disease [2–5]. UPSC, CC, and grade 3 endome-
trioid adenocarcinoma represent 10–27% of incident
endometrial cancer cases, but account for over 70% of
endometrial cancer deaths [6].
The National Comprehensive Cancer Network (NCCN)
and the Society of Gynecologic Oncology (SGO) support
pelvic and para-aortic lymphadenectomy for patients with
high-grade endometrial cancer, including UPSC, CC, and
grade 3 endometrioid adenocarcinoma [7–9]. Although
the surgical guidelines are clear, there is a demonstrated
racial disparity between Whites and Blacks in de facto
surgical management [10]. Black women are less likely to
undergo surgery for endometrial cancer [11–13]. While
* Correspondence: jonathan.foote@dm.duke.edu
1Division of Gynecologic Oncology, Duke University Medical Center, 2301
Erwin Rd, Durham, NC 27710, USA
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Foote et al. Gynecologic Oncology Research and Practice  (2017) 4:1 
DOI 10.1186/s40661-016-0036-3
many authors have examined associations between
race and the epidemiology, treatment, and outcomes
of endometrial cancer, no author has explored the re-
lationship between race and the type of surgery per-
formed. Disparities also exist for the distance traveled
to receive care for endometrial cancer, although the
available data are limited. In 2011, Benjamin et al.
performed a statewide analysis of endometrial cancer
care in Arizona and found that minorities travel far-
ther than Whites to receive care, while patients with
government-funded insurance travel farther than pa-
tients with other types of insurance [14]. There are
no other regional or national studies examining the
relationship between receipt of care for endometrial
cancer and travel distance. Based on the NCCN and
the SGO recommendations of lymph node sampling
during the surgical staging of high-grade endometrial
cancer, we explored surgical practice patterns and dis-
parities in the treatment of UPSC, CC, and grade 3
endometrioid adenocarcinoma in the United States.
Methods
Data source
The National Cancer Data Base (NCDB) is a national
oncology outcomes database in the United States,
founded in 1989 by the American College of Surgeons
(ACS) and its Commission on Cancer (CoC) Program.
One of the largest cancer registries in the world, the
NCDB collects data on 70% of all new cancer diagnoses
in the U.S. from over 1,500 reporting hospitals [15]. The
NCDB data coding process is standardized according to
the CoC Registry Operations and Data Standards Man-
ual, the American Joint Committee for Cancer (AJCC)
Manual for Staging of Cancer, and the International
Classification of Disease for Oncology, Third Edition
(ICD-O3). For the current study, all data were extracted
from medical records by trained and certified tumor regis-
trars. Our Institutional Review Board granted this study
an exemption status due to the de-identified nature of the
dataset.
Case selection
The NCDB Participant User File was searched for all
patients who underwent surgery for UPSC, CC, or
grade 3 endometrioid adenocarcinoma. Data were avail-
able from the years 1998 to 2012. Demographic and socio-
economic information was recorded for each patient,
including age, race, income, education and insurance
status. Clinical and pathologic data collected included
International Federation of Gynecology and Obstetrics
(FIGO) staging, Charlson-Deyo comorbidity score, num-
ber of regional lymph nodes examined, number of para-
aortic lymph nodes examined, peritoneal cytology status,
and performance of omentectomy. While FIGO staging
criteria were updated in 2009, we did not reclassify pa-
tients for our analysis. The FIGO 2009 staging criteria
changes to Stage I would not alter our Stage I designa-
tion; and changes to Stage II and Stage III designation
could not be fully addressed from data available in the
NCDB. Patients were further categorized based on
treatment center type (academic research center, com-
munity cancer program/other, comprehensive commu-
nity cancer program), hospital endometrial cancer
surgical volume, and distance travelled to receive care
(≤ or > 30 miles). Surgical volume was defined based on
strategies previously utilized in NCDB-related publica-
tions [16]. Hospital surgical volume was annualized
based on the total number of endometrial cancer pa-
tients and the total number of years of reported data.
Surgical volume groups were then categorized by quar-
tile rank: 75th percentile = very-high volume (>31.7
cases/year); 51st–75th percentile =moderately-high volume
(13.3–31.6 cases/year); 25th–50th percentile = intermediate
volume (6.7–13.2 cases/year); and <25th percentile = low
volume (<6.7 cases/year). While distance to care was re-
corded continuously in the NCDB, we stratified distance in
two groups, ≤ 30 miles and > 30 miles, based on the overall
mean distance traveled (mean = 30).
Statistical analysis
The main outcomes examined were the rates of lymph
node sampling and overall survival (OS). Multivariate
logistic regression was used to explore differences in
receipt of lymph node sampling (LNS). Stage IV patients
were excluded as LNS may not always be necessary or
indicated in this patient population. Given that there is
not a standard number of sampled lymph nodes to consti-
tute ‘adequate’ staging, we performed a sensitivity analysis
using replicate logistic models considering various cut
points for the number of lymph nodes sampled: (1) 0 vs. 1
+; (2) 0–1 vs. 2+; (3) 0–4 vs. 5+; (4) 0–9 vs. 10+; (5) 0–14
vs. 15+; (6) 0–19 vs. 20+. In addition, logistic regression
modeling was used to explore a subset of patients with
available data on para-aortic LNS. The following variables
were assessed for possible associations with receipt of
LNS (as categorized by the NCDB): race (White, Black,
other), median-household income (defined based on a
specific patient’s zip code at the time of diagnosis com-
pared against 2012 American Community Survey data:
<$38,000; $38,000 to $47,999; $48,000 to $62,999; or >
$63,000), education (defined as the percentage of the
population with a high school diploma as the highest
degree obtained in a specific patient’s zip code: ≥21%,
13–20%, 7–12.9%, or <7%), insurance status (not in-
sured, private insurance, Medicaid, Medicare, or other),
Charlson-Deyo comorbidity score (Charlson score of 0,
1, or ≥2), type of treatment center (comprehensive
Foote et al. Gynecologic Oncology Research and Practice  (2017) 4:1 Page 2 of 8
Table 1 Patient characteristics of patients with UPSC, CC, or grade 3 endometrioid carcinoma
Overall Black White Other p-
valuesn (%) n (%) n (%) n (%)
Total 42,973 (100)a 5,285 (12.2) 35,694 (76.1) 1,417 (3.3)
Age at diagnosis
Mean (SD) 66.0 (11.5) 65.7 (11.7) 66.2 (11.7) 61.5 (11.6) <0.001
Income
< $38,000 7,708 (17.9) 2,352 (44.5) 5,119 (14.3) 167 (11.8) <0.001
$38,000–$47,999 9,814 (22.9) 1,175 (22.2) 8,304 (23.3) 216 (15.2)
$48,000–$62,999 11,218 (26.1) 921 (17.4) 9,747 (27.3) 375 (26.5)
≥ $63,000 13,192 (30.7) 707 (13.4) 11,668 (32.7) 627 (44.2)
Unknown 1,041 (2.4)
Insurance status
Uninsured 1,418 (3.3) 256 (4.8) 1,060 (3.0) 81 (5.7) <0.001
Private Insurance 17,582 (40.9) 1,807 (34.2) 14,845 (40.6) 683 (48.2)
Medicaid and Medicare 22,750 (52.9) 3,081 (58.3) 18,823 (52.7) 578 (40.8)
Other 282 (0.7) 30 (0.6) 218 (0.6) 33 (2.3)
Unknown 941 (2.2)
Educationb
≥ 21% 7,196 (16.7) 1,928 (36.5) 4,881 (13.7) 318 (22.4) <0.001
13–20% 10,792 (25.1) 1,923 (36.4) 8,393 (23.5) 344 (24.3)
7.0–12.9% 13,867 (32.3) 933 (17.7) 12,314 (34.5) 413 (29.1)
< 7.0% 10,107 (23.5) 373 (7.1) 9,277 (26.0) 310 (21.9)
Unknown 1,011 (2.4)
Charlson-Deyo Score
0 24,653 (57.4) 2,858 (54.1) 20,540 (57.5) 890 (62.8) <0.001
≥ 1 8,128 (18.9) 1,307 (24.7) 6,465 (18.1) 258 (18.2)
Unknown 10,192 (23.7)
Histology
Uterine papillary Serous 8,238 (19.1) 1,506 (28.5) 6,413 (18.0) 211 (14.9) <0.001
Clear cell 3,631 (8.5) 576 (10.9) 2,873 (8.0) 134 (9.5)
Grade 3 endometrioid 31,104 (72.4) 3,203 (60.6) 26,408 (74.0) 1,072 (75.6)
FIGO Stage
I 24,052 (55.9) 2,622 (49.6) 20,348 (57.0) 756 (53.4) <0.001
II 4,888 (11.4) 764 (14.5) 3,911 (11.0) 152 (10.7)
III 14,033 (32.7) 1,899 (35.9) 11,435 (32.0) 509 (35.9)
Lymph node samplingc
Yes 35,158 (81.8) 4,265 (80.7) 29,211 (81.8) 1,214 (85.7) <0.001
No 7,815 (18.2) 1,020 (19.3) 6,483 (18.2) 203 (14.3)
Treatment center type
Community Cancer Program 2,647 (6.2) 269 (5.1) 2,258 (6.3) 108 (7.6) <0.001
Comprehensive Community Cancer Program 22,272 (51.8) 2,225 (42.1) 19,191 (53.8) 621 (43.8)
Academic/ Research Program 18,054 (42.0) 2,791 (52.8) 14,245 (39.9) 688 (48.6)
Hospital surgical volumed
Very–high 30,518 (71.0) 3,880 (73.4) 25,146 (70.5) 1,006 (71.0) <0.001
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community cancer program, community cancer program/
other, or academic research center), hospital endometrial
cancer surgical volume, and distance traveled to receive
care. Receipt of peritoneal cytology and omentectomy
were inconsistently reported, and therefore excluded
from our assessment. Given limited numbers regarding
minorities other than Blacks, we grouped additional mi-
norities as ‘other’ for model parsimony. Table 1 lists pa-
tient and clinical characteristics based on race for
patients with Stage I–III disease. Categorical variables
were compared using chi-square tests. Multivariate Cox
proportional hazards regression modeling and Kaplan
Meier curves were used to assess associations between
clinical variables and OS. OS models were explored
utilizing distance to care as both continuous and di-
chotomous (≤30 miles and > 30 miles). Statistical sig-
nificance was considered a priori at a two-sided p-value
of <0.05. We defined a clinically significant difference
between categorical groups to exist if a p-value of <0.05
was associated with a ≥5% difference. Statistical ana-
lyses were conducted using SAS v. 9.3 software (SAS
Institute, Inc., Cary, NC) and survival plots were created
using Spotfire S+ v. 8.1 (TIBCO, Palo Alto, CA).
Results
Patient and cancer characteristics
A total of 53,841 patients were identified who underwent
surgery and had available lymph node status data between
1998 and 2012 for high-grade endometrial cancer, includ-
ing UPSC, CC, and grade 3 endometrioid adenocarcin-
oma. Patients were excluded from our analysis if lymph
node status was not available. After excluding Stage IV
patients, 42,973 patients were available for analysis. Table 1
lists demographic, socioeconomic, and clinical character-
istics. Grade 3 endometrioid adenocarcinoma accounted
for 31,104 cases (72%), while UPSC accounted for 8,238
cases (19%), and CC accounted for 3,631 cases (9%).
Sixty–seven percent (n = 28,940) had Stage I/II disease,
while 33% (n = 14,033) had Stage III disease. Seventy–six
percent of patients were White (n = 35,694), while 12%
were Black (n = 5,285). The majority of patients were
insured via Medicaid and Medicare (53%) or private in-
surance (41%). Most patients underwent surgery at a
comprehensive community cancer program (52%) or at
an academic/research center (42%). Seventy–one per-
cent of patients received surgery at very-high volume
centers (>31.7 cases/year). The mean distance traveled
to care was 30 miles.
Receipt of surgical staging
In our cohort of 42,973 patients, 35,158 (82%) underwent
regional LNS. In univariate analysis, receipt of care at an
academic center (84% vs 70%, p < 0.001) and at a hospital
with higher endometrial cancer surgical volume (>75th
percentile, 83% vs 71% (all others), p < 0.001) were both
associated with receipt of LNS (data not shown).
In multivariate analysis, income, distance traveled to
care, Charlson-Deyo comorbidity score, and hospital
surgical volume were all significant predictors of receipt
of LNS. The sensitivity of these results were examined
using replicate logistic models considering various cut
points for the number of lymph nodes removed, which
produced identical predictors of more complete staging
to those reported above for all replicate models (0 vs. 1
+; 0–1 vs. 2+; 0–4 vs. 5+; 0–9 vs. 10+; 0–14 vs. 15+; 0–
19 vs. 20+). Surgical volume and type of cancer center
were strongly associated with each other, and thus were
not considered concomitantly in multivariate analysis:
Surgical volume was incorporated into the multivariate
model. Receipt of LNS was less likely in patients with a
Charleson-Deyo comorbidity score of ≥1 (OR 0.73, 95%
CI 0.68 to 0.78) (Table 2), or with an annual income ≤
$38,000 (38 k-$47,999: OR 1.08, 95% CI 0.98 to 1.18;
$48 k-$62,999: OR 1.20, 95% CI 1.10 to 1.32; >$63 k: OR
1.33, CI 1.21 to 1.46). Compared to very-high volume
hospitals (>31.7 cases/year), receipt of LNS was also less
Table 1 Patient characteristics of patients with UPSC, CC, or grade 3 endometrioid carcinoma (Continued)
Moderately–high 7,998 (18.6) 926 (17.5) 6,709 (18.8) 296 (20.9)
Intermediate 3,272 (7.6) 379 (7.2) 2,796 (7.8) 83 (5.9)
Low 1,185 (2.8) 100 (1.9) 1,043 (2.9) 32 (2.2)
Distance to care
≤ 30 miles 31,645 (73.6) 4,246 (80.3) 25,884 (72.5) 1,152 (81.3) <0.001
> 30 miles 10,366 (24.1) 913 (17.3) 9,025 (25.3) 234 (16.5)
Unknown 962 (2.3)
aRace data is available for 42,396 patients
bDefined as the percentage of the population with a high school diploma in a specific patient’s area code
cDefined based on the number of regional lymph nodes sampled during surgery. Yes = 1+; No = 0
dSurgical volume groups were identified based on quartile rank of the total number of endometrial cancer patients undergoing surgery and the total number of
years of reported data: 75th percentile = very-high volume (>31.7cases/year); 51st–75th percentile =moderately-high volume (13.3–31.6 cases/year); 25th–50th
percentile = intermediate volume (6.7–13.2 cases/year); and <25th percentile = low volume (<6.7 cases/year)
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likely in patients receiving surgical care at moderately-
high volume hospitals (OR 0.65, 95% CI 0.61 to 0.71),
intermediate volume (OR 0.51, 95% CI 0.45 to 0.56), or
low volume (OR 0.39, 95% CI 0.33 to 0.45). Receipt of
LNS was more likely in patients who traveled >30 miles
to receive their care (OR 1.12, 95% CI 1.04 to 1.21).
In our subset analysis of receipt of para-aortic LNS,
there were 11,068 evaluable patients with para-aortic
lymph node sampling status recorded. A total of 5,554
(50%) patients underwent para-aortic LNS. Significant
predictors of receipt of para-aortic LNS were similar to
our main model, including Black race not being associ-
ated with a difference in receipt of para-aortic LNS (OR
1.03, 95% CI 0.92 to 1.16) (Table 3).
Overall survival
Multivariate Cox proportional hazards analysis was per-
formed to identify predictors of overall survival while
controlling for patient age, race, income, receipt of
lymph node staging, stage of disease, adjuvant chemo-
therapy or radiation, hospital surgical volume, and dis-
tance to care (Table 4). A total of 31,647 patients had
sufficiently matured data available for survival analysis.
Compared to Stage I/II disease, Stage III disease was as-
sociated with lower overall survival (HR 3.39, 95% CI
3.28 to 3.50) (Fig. 1a). Patients who received LNS had
improved overall survival (HR 0.61, 95% CI 0.59 to 0.64)
(Fig. 1b). Although LNS was more common at higher
volume surgical centers, surgical volume was not a sta-
tistically significant predictor of overall survival (Table 4).
Black women compared to White women had a poorer
overall survival (HR 1.36, 95% CI 1.29 to 1.42) (Fig. 1c).
While patients who traveled >30 miles were more likely
to receive LNS, distance to care was not associated with
overall survival (HR 1.00, 95% CI 0.99 to 1.00, p = 0.758)
(Fig. 1d).
In our multivariate subset analysis of para-aortic
LNS, significant predictors of OS were similar to our
main model, including Black race (HR 1.27, 95% CI
1.10 to 1.46). Other significant predictors included
Stage III/disease (HR 3.14, 95% CI 2.80 to 3.52) and re-
ceipt of para-aortic LNS (HR 0.65, 95% CI 0.59 to 0.73).
Similar to our main cohort, surgical volume and dis-
tance to care were not associated with OS.
Table 2 Multivariate predictors of receipt of lymph node
sampling in UPSC, CC, and grade 3 endometrioid carcinoma
Predictors Odds Ratio (Reference =1) 95% CI p-value
Race
White Reference 0.21
Black 0.97 0.88–1.06
Other 1.15 0.96–1.36
Income
< $38,000 Reference <0.001
$38,000–$47,999 1.08 0.98–1.18
$48,000–$62,999 1.20 1.10–1.32
≥ $63,000 1.33 1.21–1.46
Surgical Volumea
Very high Reference <0.001
Moderately high 0.65 0.61–0.71
Intermediate 0.51 0.45–0.56
Low 0.39 0.33–0.45
Charlson-Deyo score
0 Reference <0.001
1 0.73 0.68–0.78
Distance to care
≤ 30 miles Reference 0.0025
> 30 miles 1.12 1.04–1.21
aSurgical volume groups were identified based on quartile rank: 75th percentile =
very-high volume (>31.7cases/year); 51st–75th percentile = moderately-high
volume (13.3–31.6 cases/year); 25th–50th percentile = intermediate volume
(6.7–13.2 cases/year); and <25th percentile = low volume (<6.7 cases/year)
Table 3 Multivariate predictors of receipt of para-aortic lymph
node sampling in UPSC, CC, and grade 3 endometrioid carcinoma
Predictors Odds Ratio (Reference =1) 95% CI p-value
Race
White Reference 0.79
Black 1.03 0.92–1.16
Other 1.05 0.86–1.28
Income
< $38,000 Reference
$38,000–$47,999 1.12 0.99–1.26 <0.001
$48,000–$62,999 1.23 1.09–1.38
≥ $63,000 1.34 1.18–1.50
Surgical Volumea
Very high Reference <0.001
Moderately high 0.79 0.72–0.88
Intermediate 0.72 0.61–0.85
Low 0.57 0.46–0.72
Charlson-Deyo score
0 Reference <0.001
1 0.69 0.63–0.76
Distance to care
≤ 30 miles Reference 0.069
> 30 miles 1.09 0.99–1.19
aSurgical volume groups were identified based on quartile rank: 75th percentile =
very-high volume (>31.7cases/year); 51st–75th percentile = moderately-high
volume (13.3–31.6 cases/year); 25th–50th percentile = intermediate volume
(6.7–13.2 cases/year); and <25th percentile = low volume (<6.7 cases/year)
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Discussion
The management of high-grade endometrial cancer re-
lies on the cornerstone of surgical staging. The NCCN
recommends that surgical staging for high-grade endo-
metrial cancer, including UPSC, CC, and grade 3 endo-
metrioid adenocarcinoma, consist of pelvic and para-
aortic lymphadenectomy [7]. This removal of lymph
nodes also affords the opportunity to appropriately
tailor adjuvant therapy. In this cohort of high-grade
endometrial cancer patients, our data, after controlling
for the receipt of adjuvant therapy, demonstrate that re-
ceipt of regional LNS is associated with improved sur-
vival (HR 0.61, 95% CI 0.59 to 0.64). A number of
observational studies have also shown that women who
undergo lymph node staging have improved clinical
outcomes [17–20]. While the interpretation of such ob-
servational studies is heavily limited by selection bias,
and no randomized trials specific to a high-risk hist-
ology cohort have been performed, the removal of
lymph nodes not only follows NCCN recommendations
for women with UPSC, CC, and grade 3 endometrioid
adenocarcinoma, but also guides the use of appropriate
adjuvant therapy [7]. Therefore, the lower rates of
NCCN-recommended staging of high-grade endomet-
rial cancer at lower surgical volume centers and among
lower income women is a point of concern.
Epidemiological studies have demonstrated that Black
women, as compared to White women, are dispropor-
tionately affected by high-risk histologic types of endo-
metrial cancer and are less likely to undergo surgical
management [11–13, 21–24]. Our study is the first to
examine factors associated with the receipt of LNS as
part of surgical management, and demonstrates that
receipt of LNS for high-grade endometrial cancer is
similar among Blacks and Whites (81% vs 80%, respect-
ively). While disparities in the surgical management of
high-risk endometrial cancer have improved, Black
women, compared to White women, have worse overall
survival (Table 4) (OR 1.36, 95% CI 1.29 to 1.42).
Prior studies have also demonstrated that women with
endometrial cancer are more likely to undergo lymph
node dissection at high-volume hospitals compared to
low-volume hospitals (66% vs 35%, p < 0.001) [25]. How-
ever, treatment at high-volume centers has not been
shown to improve overall survival [25–27]. Our data
support these prior findings with the highest surgical
volume centers significantly associated with receipt of
LNS, but not resulting in an improved survival. How-
ever, lymph node staging remains a key component of
surgical staging for endometrial cancer; and allows for
tailoring of adjuvant therapies. Adherence to similar
treatment guidelines in ovarian cancer has been
Table 4 Multivariate predictors of overall survival in UPSC, CC,
and grade 3 endometrioid carcinoma
Predictors Hazard Ratio
(Reference = 1)
95% CI p-value
Stage
I/II Reference
III 3.39 3.28–3.50 <0.001
Age
10-year increase 1.63 1.61–1.66 <0.001
Race
White Reference <0.001
Black 1.36 1.29–1.42
Other 0.92 0.83–1.02
Income
< $38,000 Reference <0.001
$38,000–$47,999 0.96 0.91–1.01
$48,000–$62,999 0.92 0.88–0.97
≥ $63,000 0.83 0.79–0.87
Lymph node sampling
No Reference <0.001
Yesa 0.61 0.59–0.64
Surgical Volume
Highest (4th) Quartile Reference 0.59
Third Quartile 0.97 0.94–1.02
Second Quartile 1.02 0.96–1.08
Lowest (1st) Quartile 1.01 0.91–1.11
Distance to careb
10-mile increase 1.00 0.99–1.00 0.48
aDefined based on the number of regional lymph nodes sampled during
surgery. Yes = 1+; No = 0
b“Great circle” distance: defined as the distance between the reporting
hospital and the patient’s zip code centroid. Defined here continuously.
Results were similar when distance was defined as ≤30 miles versus >30 miles
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Fig. 1 Multivariate predictors of overall survival in high-grade endometrial
cancer. a. Overall survival curve based on stage of disease. b. Overall
survival curve based on receipt of lymph node sampling. c. Overall
survival curve based on race (White vs. Black). d. Overall survival curve
based on distance to care (≤30 miles vs. >30 miles)
Foote et al. Gynecologic Oncology Research and Practice  (2017) 4:1 Page 6 of 8
associated with proximity to care, although similar re-
ports are not available for endometrial cancer [28]. In
our analysis, women with high-grade endometrial cancer
who traveled farther for their surgical care were more
likely to receive LNS (OR 1.12, 95% CI 1.04 to 1.21).
Interestingly, 84% of women who traveled >30 miles for
care received care at the highest volume centers. Our
findings suggest that patients may have traveled farther
initially to seek the surgical expertise of higher volume
centers, thereby explaining the higher rates of LNS ob-
served among those who traveled farther.
Several limitations to our study are inherent in the
use of large clinical and administrative databases. While
the Charlson-Deyo score accounts for comorbidities,
the NCDB does not record data on body mass index
(BMI), which can influence surgical decision making.
Additionally, there was inadequate reporting of omen-
tectomy and peritoneal cytology to include in our ana-
lysis. Another limitation is interpretation of the number
of lymph nodes examined. The NCDB reports the number
of lymph nodes examined by a pathologist; however, infor-
mation distinguishing between pelvic and para-aortic
nodal basins is largely incomplete. As sentinel lymph node
mapping is being utilized more often in endometrial can-
cer, the number of lymph nodes needed for adequate sur-
gical staging is likely to decrease while lymph node status
becomes even more vital to the management and progno-
sis of endometrial cancer. In order to broadly examine the
surgical staging issue without focusing on nodal counts,
we chose to examine lymph node staging as a dichotom-
ous variable.
Conclusions
Lymph node staging for high-grade endometrial cancer,
whether comprehensive lymphadenectomy or sentinel
lymph node mapping, is not only recommended by the
NCCN and the SGO, but can also assist in the tailoring
of adjuvant therapies. While medical comorbidities (as
captured here in the Charlson-Deyo score) may provide
inherent difficulties to completing surgical staging, the
receipt of guideline-based care should not be limited.
High-volume centers are best equipped to provide
guideline-based care to these high-risk women.
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